This Is MS Multiple Sclerosis Community: Knowledge & Support

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.
It is currently Wed May 22, 2013 6:49 am

View unanswered posts | View active topics


Board index » Multiple Sclerosis » Drug Pipeline

All times are UTC - 8 hours [ DST ]



Post new topic Reply to topic  Page 1 of 1
  [ 1 post ] 
  Print view Previous topic | Next topic 
Author Message
rainer
PostPosted: Mon Jan 28, 2008 5:38 pm 
Offline
Family Elder
User avatar

Joined: Thu Jan 17, 2008 4:00 pm
Posts: 367
<shortened url>

Acorda Therapeutics (nasdaq: ACOR - news - people ) said its multiple sclerosis drug Fampridine-SR does not raise the risk of heart-related side effects anymore than a placebo in a so-called QT cardiac safety study required by the U.S. Food and Drug Administration. Acorda shares were up 20.1%, or $4.38, at $26.16, in afternoon trading.
Top
 Profile  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  Page 1 of 1
  [ 1 post ] 

Board index » Multiple Sclerosis » Drug Pipeline

All times are UTC - 8 hours [ DST ]

Related topics
 Topics   Author   Replies   Views   Last post 
There are no new unread posts for this topic. Another candidate treatment successfully passes phase I

dignan

0

1325

Tue Apr 05, 2005 9:13 am

dignan View the latest post

 


Who is online

Users browsing this forum: No registered users

You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum

Search for:
Jump to: